Anticancer agent 232
Anticancer agent 232 (compound 12f) is a glycohybrid designed using 1-azidoglycosides derived from d-glucose, d-galactose, and d-mannose. The IC50 values of anticancer agent 232 against MCF-7 and MDA-MB231 cells are 1.05 μM and 18.03 μM, respectively[1].
Product Specifications
CAS Number
9007-83-4
UNSPSC
12352005
Target
Endogenous Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-232.html
Smiles
O=C(C1=CC=CO1)/C=C/C2=CN(CC3=CN([C@H]4O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]4OC(C)=O)N=N3)C5=CC=C(Br)C=C52
Molecular Formula
C32H31BrN4O11
Molecular Weight
727.51
References & Citations
[1]Tyagi R, et al. Efficient synthesis of indole-chalcones based glycohybrids and their anticancer activity. Bioorg Med Chem. 2024 Jul 15;109:117778.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Browse additional items from our catalog
PAICSP1 sgRNA CRISPR Lentivector (Human) (Target 3)
EEF1E1 (Eukaryotic Translation Elongation Factor 1 Epsilon-1, P18, AIMP3) discontinued